Ethoxyquin

Kinase experiment:

To evaluate the impact of Ethoxyquin (EQ) on Paclitaxel’s (PTX’s) ability to kill breast cancer cells, conditions for culturing 4 cancer cell lines and measuring the ATP levels are optimized for the 96-well plate format. Briefly, 1,500 cells/well in media are plated in 96-well plates for 24 hours. Constant concentrations of PTX with or without Ethoxyquin are added to the wells for another 24 hours. Cellular ATP levels are measured using kit according tomanufacturer ’s protocol[2].

Cell experiment:

Briefly, DRGs are harvested from embryonic day 14.5 rats according to standard protocols, then cells are plated onto collagen-coated glass coverslips and allowed to extend neurites for 24 hours in media (Neurobasal medium, 50 mM pencillin-streptomycin (PS), 0.2% FBS, 0.5 mM glutamine, 1×B-27 supplement, 0.2% glucose,10 ng/mL glial cell line-derived neurotrophic factor). Ethoxyquin (EQ) or vehicle control is added to the wells for another 24-hour incubation. DRG cells are fixed with 4% paraformaldehyde and stained with anti-βIII-tubulin antibody to delineate the axons. Axon lengths are measured in multiple fields using a random sampling method[2].

Animal experiment:

To examine the effect of Ethoxyquin (EQ) on Paclitaxel’s (PTX’s) ability to reduce tumor burden in vivo, a mouse model in which breast cancer cell line SUM-159 (3×106 tumor cells suspended in phosphate-buffered saline in a final volume of 0.15 mL) is injected subcutaneously into adult male nude mice. When the tumor size reaches 5 mm in diameter, the animals are randomly assigned to PTX or PTX with Ethoxyquin groups. Ethoxyquin is given by intraperitoneal administration on a daily basis for 3 weeks. At the end of 3 weeks, animals are euthanized and tumor size and weight are measured (n=5 per group)[2].

References:

[1]. Sadikot T, et al. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol. 2013 Oct;11(8):478-88.
[2]. Zhu J, et al. Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation. Ann Neurol. 2013 Dec;74(6):893-904.
[3]. Zhu J, et al. Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. Sci Rep. 2016 Jun 28;6:28861.